ERBB2 and gastric cancer: The ongoing phase 2/3 KN026-CSP-001 study (NCT05427383) will evaluate the safety and efficacy of KN026 in combination with chemotherapy in patients with HER2-positive (IHC 3+ or IHC 2+ with ISH positivity) gastric cancer who have progressed on from or have undergone a trastuzumab-containing regimen in China.